Business Wire

ADVA

Share
ADVA showcases 400ZR DCI solution with Acacia and Inphi

ADVA (FSE: ADV) today announced that it has successfully demonstrated interoperability between its next-generation FSP 3000 DCI open line system (OLS) and QSFP-DD 400ZR modules from Acacia Communications and Inphi Corporation. Conducted over a 120km amplified link, the tests show a clear path to commercial deployments of a complete solution with all the benefits of open, programmable networking. The trial featured 400Gbit/s WDM transport using low-power 400ZR pluggable QSFP-DD transceivers from Acacia and Inphi with ADVA’s FSP 3000 DCI OLS . It was carried out under real-world conditions with 400Gbit/s channels placed next to the test channels as well as a fully loaded spectrum. To validate three-way line-side interoperability, 400ZR was transmitted from Acacia to Inphi and vice versa. Test results showed that this multi-vendor ecosystem exceeds all OIF 400ZR Implementation Agreement performance metrics. Large-scale DCI network operators now have an easy and cost-effective route to a dynamic, future-proof and open environment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005107/en/

“Today, we’re showing a direct route to open DCI networking using 400ZR. By proving the next-level interoperability of our platform with Acacia and Inphi’s optical interconnect technology, we’re empowering network operators to effortlessly harness the benefits of both 400ZR and open infrastructure. This will be key to reducing cost and complexity in the new breed of high-bandwidth DCI networks,” said Steve Penticost, VP, global business development, ADVA. “Others may talk about openness, but our track record with multi-vendor innovation speaks for itself. With thousands of our DCI OLS deployed, we’re already giving huge numbers of networks across the planet the freedom to select any components and leverage different innovation cycles.”

The ADVA FSP 3000 DCI OLS is the market’s most comprehensive OLS platform. Its open and modular design removes all restrictions of traditional closed systems and puts DCI network operators in complete control. With ADVA’s unrivalled experience of managing APIs in DCI architectures, the platform extends SDN to the transport layer. Designed to interoperate with all standards-based DWDM pluggable optics, the ADVA DCI OLS now features components specifically engineered to meet 400ZR DCI demands. The latest trials using a 120km single-mode fiber show that it exceeds 400ZR performance requirements under fully loaded conditions including 75GHz channel spacing, enabling an aggregate capacity of 26Tbit/s per fiber. ADVA’s DCI OLS and Acacia and Inphi’s QSFP-DD 400ZR modules offer operators a complete and validated solution built on best-of-breed components.

“Acacia has a long, proven history of pluggable silicon photonics innovation and has continually driven down the level of power consumption, size and cost of coherent interconnects,” said Tom Williams, VP, marketing, Acacia Communications. “400Gbit/s coherent pluggables enable network operators to support their growing bandwidth demands using power-efficient solutions that offer operational flexibility. By showcasing the interoperability of our high-performance coherent platform in a QSFP form factor with ADVA’s new DCI OLS, we’re giving DCI networks a clear path to a compact and cost-efficient optical layer assembled with best-in-class innovation.”

“With the introduction of COLORZ® 100G in 2016, Inphi’s silicon photonics-based QSFP transceivers along with ADVA’s line systems created a simpler and more cost-efficient way to connect data centers. Inphi’s COLORZ® II 400ZR QSFP-DD transceiver, with its low-power coherent DSP and silicon photonics engine, takes IP over DWDM to the next level. COLORZ® II 400ZR enables large cloud operators to connect metro data centers at a fraction of the cost of traditional coherent transport systems and allows switch and router companies to offer the same density for both coherent DWDM and client optics in the same chassis. Interoperable 400ZR solutions allow customers to deploy a validated ecosystem with our innovative low-power, high-performing pluggable solutions and ADVA’s next-generation DCI OLS,” said Josef Berger, AVP, optical interconnect, Inphi. “400ZR empowers DCI operators to select best-in-class components that reduce the total cost of ownership of their cloud networks.”

More information on the demo is available in these slides: https://adva.li/acacia-inphi-demo-slides .

Watch this video for further details on the new ADVA DCI OLS: https://youtu.be/8zI3E46oMBo .


About ADVA

ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

All trademarks used herein are the property of their respective owners.

Social Media:

https://www.facebook.com/pages/ADVA-Optical-Networking/37630238931

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release

Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye